Eli Lilly Reports Positive Early Results for Gene‑Editing Cholesterol Therapy
By Adriano Marchese
Eli Lilly said it received positive results from its phase 1b clinical trials for its experimental gene editing treatment for high cholesterol.
The pharmaceutical company said Monday that a single infusion of the therapy called Verve-102 reduced PCSK9 protein levels by up to 88% and lowered LDL cholesterol by as much as 62% in a phase 1b study of adults with heterozygous familial hypercholesterolemia, or premature coronary artery disease.
The treatment uses in vivo base editing to effectively turn off the PCSK9 gene in the liver, mimicking naturally occurring genetic variants that protect against heart disease. The Food and Drug Administration has granted fast-track designation to the treatment.
Eli Lilly said that results were sustained for as long as 18 months, and no treatment-related serious adverse events were reported.
The company plans to start a phase 2 clinical study of Verve-102 by the end of the year.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
May 25, 2026 09:39 ET (13:39 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
These Overvalued Stocks Have Plenty of Room to Fall
Your Year-End Financial Checklist: 5 Things to Tackle Before 2027
The 10 Best Companies to Invest in Now
4 Big Impacts From the US Midterm Elections for Investors
United States